How Zero Markups Work: A Closer Look At Public Hospital Reform In Shenzhen

Shenzhen, China's testing ground for hospital reform, is also experimenting with a factory-direct sales model, which could create "absolute chaos" for pharma companies, according to the Monitor Group.

SHANGHAI – After three years of implementing its healthcare reforms, China's basic medical insurance now covers 1.3 billion people – nearly all of China. This year, the government has targeted public hospital reform as one of its main goals, and the city of Shenzhen is serving as a testing ground for many reforms, most recently for the removal of drug price markups in all public hospitals.

The main goal of eliminating drug markups is to delink hospital revenues from pharmaceutical sales, which is then expected to...

More from China

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Focus On Asia